This article is more than 5 years old. Information may no longer be current.
Immune Pharmaceuticals provides updates on atopic dermatitis, psoriasis treatments
Click Here to Manage Email Alerts
Immune Pharmaceuticals recently provided an update on treatments for atopic dermatitis and psoriasis as part of its first quarter financial report.
Immune reported on products including bertilimumab, currently in two phase 2 clinical trials for treating ulcerative colitis and bullous pemphigoid, and a third phase 2 trial planned for treating severe atopic dermatitis, according to a press release. It reported it is continuing enrollment in two phase 2 clinical trials for bertilimuamb.
"We continue to progress in our clinical trials with bertilimumab as we increase patient enrollment and we are on track to achieve our operational and financial objectives for 2016,” Daniel Teper, PharmD, CEO of Immune Pharmaceuticals, stated in the release.
Immune also reported on its “immune-inflammation” focus on topical nano-formulated cyclosporine for treating atopic dermatitis and psoriasis. Immune reported that it is developing topical nano-formulated cyclosporine “toward an investigational new drug application and initiation of 505(b) 2 clinical development,” according to the release.
Immune reported a loss attributable to common stockholders of $6 million, or $0.17 per share, for the quarter ending March 31, compared to a loss attributable to common stockholders of $3.6 million, or $0.15 per share, for the same time period in 2015, according to the press release.
There was an increase of $0.9 million for research and development expenses, due to higher salaries and employee benefits, license fees and clinical trial expenses, according to the release.
Reference: www.immunepharmaceuticals.com